University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Laura Esserman, M.D.

Director of the Carol Franc Buck Breast Care Center

Dr. Laura Esserman, a nationally known breast surgeon, is the director of the UCSF Carol Franc Buck Breast Care Center at the Mount Zion campus. Her work is devoted to developing new, more effective ways to care for and empower breast cancer patients during treatment and to tailor treatments using biology, personal preference and constant feedback regarding outcomes of care.

Esserman earned an undergraduate degree at Harvard University and completed medical and surgical training at Stanford University. She completed a postdoctoral fellowship in breast oncology at Stanford in 1988 and earned a master's degree at the Stanford Graduate School of Business in 1993. She joined UCSF Medical Center in 1993. Esserman is a profesor of surgery and radiology in the UCSF School of Medicine.

Clinics

Carol Franc Buck Breast Care Center
1600 Divisadero St., Second Floor
San Francisco, CA 94115
Phone: (415) 353-7070
Surgery Fax: (415) 353-7050
Oncology Fax: (415) 353-7692

Hours: Monday to Friday
8 a.m. – 5 p.m.

Cancer Risk Program
1600 Divisadero St., Second Floor
San Francisco, CA 94143-1714
Phone: (415) 885-7779
Fax: (415) 885-3787

Hours: Monday to Friday
9 a.m. – 5 p.m.

Conditions & Treatments

More about Laura Esserman

Additional Languages

Spanish

Education

Stanford University 1983

Residencies

Stanford University, General Surgery 1991

Selected Research and Publications

  1. Wells CJ, O'Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman LJ. Evolving Paradigm for Imaging, Diagnosis, and Management of DCIS. J Am Coll Radiol. 2013 Dec; 10(12):918-23.
  2. Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman LJ, Ozanne EM. Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery. Breast Cancer Res Treat. 2014 Jan; 143(1):135-40.
  3. Eklund M, Esserman LJ. Screening: Biology dictates the fate of young women with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):673-5.
  4. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, Van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114.
  5. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med. 2013 Oct 28; 173(19):1830-1.
  6. Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013 Aug 28; 310(8):797-8.
  7. Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total Skin-Sparing Mastectomy in BRCA Mutation Carriers. Ann Surg Oncol. 2014 Jan; 21(1):37-41.
  8. Elson SL, Hiatt RA, Anton-Culver H, Howell LP, Naeim A, Parker BA, Van't Veer LJ, Hogarth M, Pierce JP, Duwors RJ, Hajopoulos K, Esserman LJ. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care. Breast Cancer Res Treat. 2013 Jul; 140(2):417-25.
  9. Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013 Sep; 20(9):2873-80.
  10. Mukhtar RA, Yau C, Rosen M, Tandon VJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30.
  11. Flowers CI, O'Donoghue C, Moore D, Goss A, Kim D, Kim JH, Elias SG, Fridland J, Esserman LJ. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention. Breast Cancer Res Treat. 2013 Jun; 139(3):769-77.
  12. O'Donoghue C, Esserman L. Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement. Br J Cancer. 2013 Jun 11; 108(11):2200-1.
  13. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 1; 19(11):2817-23.
  14. Peled AW, Esserman LJ. Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy. Plast Reconstr Surg. 2013 Feb; 131(2):279e.
  15. Pass M, Volz S, Teng A, Esserman L, Belkora J. Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions. J Cancer Educ. 2012 Dec; 27(4):764-9.
  16. Esserman L, Ozanne E, van't Veer L. Will early detection for breast cancer ever work? Clin Chem. 2013 Jan; 59(1):190-3.
  17. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9.
  18. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 1; 31(7):961-5.
  19. Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res. 2012 Dec 1; 18(23):6426-35.
  20. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.